Literature DB >> 17069524

Anti-VEGF therapy: a new approach to colorectal cancer therapy.

Alfredo Carrato1, Javier Gallego-Plazas, Carmen Guillen-Ponce.   

Abstract

The purpose of this review is to discuss the inhibition of vascular endothelial growth factor as a treatment for advanced colorectal cancer. The review will begin by summarizing the theory behind vascular endothelial growth factor inhibition and how this affects tumor angiogenesis. The major clinical trials that have examined antivascular endothelial growth factor agents to treat patients with advanced colorectal cancer will then be described. Finally, there is a commentary regarding the status of targeted agents currently in development for the treatment of advanced colorectal cancer and a discussion of the potential future considerations for the use of antivascular endothelial growth factor agents in clinical practice.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17069524     DOI： 10.1586/14737140.6.10.1385

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  7 in total

1.  Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.

Authors:  Ana Fernández Montes; Carlos López López; Guillem Argilés Martínez; David Páez López; Ana María López Muñoz; Beatriz García Paredes; David Gutiérrez Abad; Carmen Castañón López; Paula Jiménez Fonseca; Javier Gallego Plazas; María Carmen López Doldán; Eva Martínez de Castro; Manuel Sánchez Cánovas; María Tobeña Puyal; Beatriz Llorente Ayala; Ignacio Juez Martel; Mariana López Flores; Alberto Carmona-Bayonas
Journal:  Oncologist       Date:  2019-05-30

2.  Anti-angiogenic effect of total saponins of Rhizoma Dioscorea nipponica on collagen induced-arthritis in rats.

Authors:  Xiu-Jun Liang; Ya-Chun Guo; Tong-You Sun; Hong-Ru Song; Ya-Xian Gao
Journal:  Exp Ther Med       Date:  2016-08-10       Impact factor: 2.447

3.  Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.

Authors:  Chenbo Ding; Longmei Li; Taoyu Yang; Xiaobo Fan; Guoqiu Wu
Journal:  BMC Cancer       Date:  2016-10-12       Impact factor: 4.430

4.  Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.

Authors:  Chenbo Ding; Junmin Luo; Xiaobo Fan; Longmei Li; Shanshan Li; Kunming Wen; Jihong Feng; Guoqiu Wu
Journal:  J Exp Clin Cancer Res       Date:  2017-04-18

5.  Application of Bevacizumab Combined With Chemotherapy in Patients With Colorectal Cancer and Its Effects on Brain-Gut Peptides, Intestinal Flora, and Oxidative Stress.

Authors:  Chao Chen; Songtao Hou; Fei Zhao; Bin Wu; Tingting Liu; Zhao Zhang; Yuwei Li; Hongchao Li
Journal:  Front Surg       Date:  2022-04-11

6.  The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC).

Authors:  Kuifeng He; Binbin Cui; Guangliang Li; Haohao Wang; Ketao Jin; Lisong Teng
Journal:  Onco Targets Ther       Date:  2012-04-13       Impact factor: 4.147

Review 7.  Vascular endothelial growth factor (VEGF) in autoimmune diseases.

Authors:  Jozélio Freire Carvalho; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2007-03-06       Impact factor: 8.542
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.